Continuous Positive Airway Pressure Devices Market Size | Companies
The continuous positive airway pressure devices market size was exhibited at USD 2.15 billion in 2024 and is projected to hit around USD 3.66 billion by 2034, growing at a CAGR of 5.46% during the forecast period 2024 to 2034.
The Continuous Positive Airway Pressure (CPAP) devices market has emerged as a cornerstone of the respiratory care industry, particularly in the management of sleep-related breathing disorders such as obstructive sleep apnea (OSA). CPAP devices function by delivering a steady stream of pressurized air through a mask, preventing airway collapse during sleep and thereby maintaining proper airflow. With increasing awareness, improved diagnostics, and rising disease prevalence, CPAP therapy has become the gold standard for non-invasive treatment of OSA.
Globally, millions remain undiagnosed or untreated for sleep apnea—a condition that significantly raises the risk of cardiovascular disease, stroke, hypertension, and type 2 diabetes. In the U.S. alone, the American Sleep Apnea Association estimates that over 22 million Americans suffer from sleep apnea, with 80% of moderate to severe cases remaining undiagnosed. As diagnostic tools improve and awareness grows, the demand for CPAP devices is experiencing consistent growth across home and clinical care settings.
The COVID-19 pandemic also served as a pivotal moment for the CPAP devices market. During peak periods, several CPAP devices were repurposed or modified as non-invasive ventilatory support tools in overwhelmed hospital ICUs, demonstrating their utility beyond sleep medicine. Furthermore, the pandemic accelerated the adoption of remote health monitoring and telemedicine—facilitating the expansion of connected CPAP devices capable of wirelessly transmitting sleep data to providers for evaluation and therapy adjustment.
Major players in the market are increasingly focused on developing compact, travel-friendly, and smart CPAP machines with Bluetooth and Wi-Fi connectivity. These innovations not only enhance patient adherence but also support long-term health monitoring and engagement. With the convergence of respiratory health, digital health technologies, and growing health consciousness, the CPAP market is poised for substantial expansion.
Increased Adoption of Connected CPAP Devices: Integration of wireless connectivity, mobile apps, and cloud platforms is enhancing therapy monitoring and patient compliance.
Miniaturization and Portability: Development of lightweight, travel-friendly CPAP devices is helping users maintain therapy adherence during travel.
Home-Based Sleep Diagnostics: Rise in home sleep testing kits is increasing CPAP therapy initiation outside traditional clinical settings.
Hybrid Connectivity Solutions: Devices offering both Bluetooth and Wi-Fi/cellular connections provide flexible options for patients and providers.
Artificial Intelligence Integration: AI-enabled CPAP devices are helping automate pressure adjustments and detect anomalies in sleep patterns.
Reimbursement Policy Expansion: Favorable insurance support in several developed economies is making therapy more accessible.
Eco-Conscious Designs and Reusability: Manufacturers are designing more sustainable and recyclable CPAP components to reduce environmental impact.
Collaborative Digital Health Platforms: Partnerships between device makers and health IT companies are fostering end-to-end sleep disorder management ecosystems.
| Report Coverage | Details |
| Market Size in 2025 | USD 2.27 Billion |
| Market Size by 2034 | USD 3.66 Billion |
| Growth Rate From 2024 to 2034 | CAGR of 5.46% |
| Base Year | 2024 |
| Forecast Period | 2024-2034 |
| Segments Covered | Connectivity, End use, Region |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
| Regional Covered | North America; Europe; Asia Pacific; Latin America; MEA |
| Key Companies Profiled | ResMed; Koninklijke Philips N.V.; Fisher & Paykel Healthcare Limited; Medical Depot, Inc. dba Drive DeVilbiss Healthcare; React Health (3B Medical); Transcend Inc. (Somnetics International, Inc.); Wellell Inc. (Apex Medical); BMC |
Rising Prevalence of Obstructive Sleep Apnea and Related Comorbidities
One of the most significant drivers of the CPAP devices market is the escalating incidence of obstructive sleep apnea (OSA) across all age groups, particularly among the aging population and individuals with obesity. As per the National Sleep Foundation, OSA is now recognized as a public health issue that extends beyond sleep quality to impact cardiovascular and metabolic health. Patients with untreated sleep apnea face a higher risk of heart attacks, strokes, atrial fibrillation, and poor glycemic control in diabetes.
The increasing burden of lifestyle-induced disorders, coupled with more accurate and accessible diagnostic tools like polysomnography and home sleep testing kits, is pushing more individuals toward treatment. CPAP therapy is not only clinically validated as an effective first-line intervention but also cost-effective over time. Its ability to improve daytime alertness, reduce accident risk, and enhance quality of life is further prompting adoption. Health systems, insurers, and clinicians are now aligning to recommend early diagnosis and CPAP adherence, contributing to sustained demand.
Therapy Non-Adherence and Patient Discomfort
Despite its clinical efficacy, CPAP therapy is often plagued by poor patient adherence, which remains a significant restraint to market expansion. Discomfort caused by the mask, claustrophobia, dry nose or mouth, noise from the device, and the need for consistent nightly use are common barriers to sustained use. Studies suggest that up to 30–50% of patients prescribed CPAP therapy fail to adhere to it beyond the first year.
Non-compliance diminishes the therapy’s effectiveness and can lead to costly readmissions, worsening health outcomes, and increased healthcare expenditure. While manufacturers are introducing noise-reduction technologies, humidification features, and better mask designs, the issue of long-term adherence remains a clinical and commercial challenge. Addressing behavioral and psychological aspects of therapy will require a more holistic approach involving patient education, counseling, and customized device options.
Surge in Demand for Home-Based Sleep Care and Remote Monitoring
The growing preference for home-based healthcare represents a substantial opportunity for CPAP device manufacturers and service providers. As telemedicine gains ground and healthcare systems shift toward decentralized care, patients are increasingly being diagnosed and treated for sleep disorders from the comfort of their homes. CPAP devices with remote monitoring capabilities—integrated with apps and cloud-based platforms—allow physicians to track patient usage, compliance, and therapeutic efficacy in real time.
This model not only improves access to therapy for patients in rural or underserved areas but also reduces the burden on hospitals and sleep centers. Companies offering connected CPAP systems that integrate with digital health platforms can build recurring revenue models through data services, subscription maintenance, and personalized therapy plans. The opportunity to offer CPAP-as-a-Service is gaining momentum in both public and private healthcare systems, aligning with trends toward value-based care.
Connected CPAP devices dominated the market and are projected to maintain leadership due to the increasing importance of data-driven respiratory care. Within this category, Wi-Fi and cellular-connected devices are widely adopted by hospitals and sleep centers due to their seamless cloud integration, allowing for real-time data transmission and proactive interventions. Bluetooth-connected CPAPs are particularly popular among home users, as they provide quick pairing with mobile apps for instant feedback. Hybrid-connected CPAPs, combining multiple connectivity options, are gaining traction for their flexibility across different care settings and travel scenarios.
Non-connected CPAP devices are the fastest-growing segment in certain emerging markets where affordability and internet infrastructure pose challenges. These devices offer a simplified, cost-effective alternative for patients who require CPAP therapy but do not need or cannot access advanced digital features. Many hospitals in developing countries still rely on non-connected CPAPs for inpatient respiratory support. As manufacturers develop budget-friendly, durable, and battery-operated models for such contexts, non-connected devices will see consistent uptake, particularly in resource-constrained environments.
The home care settings segment held the largest revenue share of over 60.00% in 2024 and is anticipated to grow at the fastest CAGR over the forecast period. The comfort and privacy of home treatment, combined with technological advances that enable self-monitoring, have made CPAP therapy more accessible and user-friendly. Patients with chronic sleep apnea often prefer to manage their condition at home, especially when supported by digital applications and regular teleconsultations. The convenience and reduced costs of avoiding repeated clinical visits are further encouraging adoption.
Hospitals and clinics represent the fastest-growing end-use segment, particularly in cases involving acute respiratory distress or sleep apnea diagnosis. CPAP therapy is often initiated in hospitals for patients undergoing post-operative recovery or non-invasive respiratory support. Moreover, in the context of infectious diseases like COVID-19, hospitals used CPAP machines as temporary ventilatory support devices. This dual application is expanding their utility in hospital respiratory care departments. Specialty sleep clinics also play a crucial role in prescribing and fine-tuning therapy, ensuring patients are correctly diagnosed and fitted for CPAP use.
North America leads the global CPAP devices market, accounting for the highest revenue share due to its advanced healthcare infrastructure, high awareness levels, and favorable reimbursement landscape. The United States, in particular, has a well-established network of sleep centers, diagnostic laboratories, and insurance systems that cover CPAP therapy for diagnosed sleep apnea. Leading manufacturers such as ResMed, Philips Respironics, and Fisher & Paykel Healthcare have their operational hubs and R&D centers located in North America, reinforcing product availability and innovation.
Further, the prevalence of obesity, a major risk factor for sleep apnea, is higher in the U.S. compared to many other nations, contributing to higher diagnosis rates. The strong presence of digital health platforms and early adoption of connected CPAP devices also position North America as a technological leader. Numerous companies have introduced AI-powered sleep analytics and cloud-enabled monitoring solutions that have revolutionized how therapy is delivered and tracked.
Asia Pacific is the fastest-growing region in the CPAP devices market, driven by rising urbanization, increasing healthcare expenditure, and growing public awareness about sleep-related disorders. Countries like China, India, Japan, and South Korea are witnessing significant demand for respiratory care devices as their populations age and lifestyles become increasingly sedentary. Government initiatives aimed at expanding healthcare access and insurance penetration are playing a crucial role in the market’s expansion.
Moreover, the region has seen a boom in private healthcare infrastructure, including the establishment of sleep labs and specialized respiratory clinics in major cities. Local manufacturers are emerging with cost-effective CPAP solutions tailored to the specific needs and purchasing capacities of the population. Partnerships between global giants and regional distributors are also increasing product accessibility, particularly in rural and semi-urban areas. The adoption of portable and non-connected CPAP devices is growing in Asia Pacific due to economic and infrastructural limitations, but connected devices are gradually making inroads in urban centers.
January 2025: ResMed introduced its next-generation AirSense 11 AutoSet CPAP machine with enhanced AutoRamp and myAir integration, aiming to improve patient compliance through personalized coaching features.
February 2025: Philips Respironics resumed production of DreamStation CPAP machines after FDA clearance post recall adjustments, ensuring safe and compliant manufacturing protocols.
March 2025: Fisher & Paykel Healthcare announced a partnership with a major telehealth provider to integrate remote CPAP monitoring into digital patient care pathways in the U.S.
April 2025: DeVilbiss Healthcare launched a new ultra-portable CPAP device for travel use, targeting frequent flyers and business travelers needing therapy on the go.
April 2025: BMC Medical (China) expanded its European distribution network by partnering with Medex Healthcare to supply Bluetooth-enabled CPAP devices across Germany and the UK.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the continuous positive airway pressure devices market
By Connectivity
By End Use
By Regional
Cross-segment Market Size and Analysis for Mentioned Segments
Additional Company Profiles
(Upto 5 With No Cost)
Additional Countries (Apart
From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers